No replies to this topic

[lucid]

Inhibition Of Human Prostate Cancer Progression By Administration Of Green Tea Catechins: A 2 Years Later Follow-Up Date[/b]

ORLANDO, FL (UroToday.com) - Prostate cancer is an ideal target for chemoprevention strategies that, at present, may be the best approach, according to a group of Italian researchers. They cite a growing body of evidence that compounds from green tea (catechins: the most common are EGCG, EGC, ECG and EC) might posses anti-tumor activity.

Recently they showed that a Green Tea Catechins extract (GTCs) was very effective at inhibiting cancer growth in vitro and in animal model, triggering apoptotic death in cancer cells probably through induction of the nuclear form of Clusterin. In 2006 they published the result of a clinical trial demonstrating that about 90% inhibition of CaP development was indeed achievable by oral administration of GTCs to humans for one year.

Although this was the first study showing that GTCs are safe and very effective for treating pre-malignant lesions, it is evident that this important result needs confirmation with a larger study. But another important issue is still open: understanding whether CaP onset was definitively prevented or simply delayed by treatment. The purpose of this study was to evaluate results the after 2 years.

In the 2006 study, a cohort of 60 human volunteers bearing HG-PIN, the main pre-malignant lesion of CaP, were given 600mg/die of GTCs (n = 30) or placebo (n = 30) for 1y. At the end of the study, only 1 tumor was diagnosed among the GTCs-treated men, while 9 cancers were found among the placebo-treated men, with no significant side or adverse effects recorded. To check whether CaP onset was definitely prevented or simply delayed by treatment, the researchers managed to convince about 50% of patients from both arms (all asymptomatic) to undergo another round of prostate mapping by needle biopsy 2ys after suspension of GTCs administration.

They detected 1 more cancer in the cohort previously belonging to the GTCs-arm, and 2 more in that once belonging to the placebo-arm. Thus, 3 years after the beginning of the study and 2 years after suspension of GTCs administration, final results were: 11cancers in untreated volunteers versus 2 in those given GTCs for 1 year.

This novel data further strengthen the researchers previous result, strongly suggesting that CaP development might be definitely inhibited in men bearing HG-PIN by administration of 600mg/day of GTCs for just 1year.

Presented by Brausi Maurizio, MD, Bettuzzi Saverio, MD, Peracchia Giancarlo, MD, Rizzi Federica, MD, and Corti Arnaldo, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

http://www.medicalne...cles/111208.php